Table 3 Observed distribution of HR-HPV infections and detected CIN2+, by HR-HPV genotype and the woman’s age

From: 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot

  

Age group

  

24–29

30–49

50–64

Total

 

N screened

23,864 (100%)

72,833 (100%)

30,541 (100%)

127,238 (100%)

 

HR-HPV genotype at baseline

    

HR-HPV infections

HR-HPV+

6709 (28%)

7646 (10%)

1742 (6%)

16,097 (13%)

HPV 16+

2111 (9%)

1588 (2%)

348 (1%)

4047 (3%)

Else HPV 18+

509 (2%)

541 (1%)

110 (<1%)

1160 (1%)

Else other HR-HPV+

4089 (17%)

5517 (8%)

1284 (4%)

10,890 (9%)

Colposcopies

HR-HPV+

4013 (17%)

3890 (5%)

856 (3%)

8759 (7%)

HPV 16+

1649 (7%)

1125 (2%)

215 (1%)

2989 (2%)

Else HPV 18+

364 (2%)

325 (<1%)

61 (<1%)

750 (1%)

Else other HR-HPV+

2000 (8%)

2440 (3%)

580 (2%)

5020 (4%)

CIN2+

HR-HPV+

1579 (7%)

1133 (2%)

147 (<1%)

2859 (2%)

HPV 16+

899 (4%)

475 (1%)

49 (<1%)

1423 (1%)

Else HPV 18+

138 (1%)

95 (<1%)

14 (<1%)

247 (<1%)

Else other HR-HPV+

542 (2%)

563 (1%)

84 (<1%)

1189 (1%)

CIN3+

HR-HPV+

980 (4%)

699 (1%)

84 (<1%)

1763 (1%)

HPV 16+

613 (3%)

324 (<1%)

31 (<1%)

968 (1%)

Else HPV 18+

82 (<1%)

62 (<1%)

9 (<1%)

153 (<1%)

Else other HR-HPV+

285 (1%)

313 (<1%)

44 (<1%)

642 (1%)

  1. CIN cervical intraepithelial neoplasia, HR-HPV high-risk human papillomavirus
Back to article page